For this, we initiated Yumm2.1 tumors in UVR animals and treated them with anti-PD-1 and anti-CD25, an antibody that depletes systemic CD25+ cells which are primarily present at high levels in Tregs, which can modestly reduce tumor growth by depleting Tregs in murine melanoma models.30 This evidence concerns the gene PDCD1 and neoplasm.